The statistical analysis showed that nesfatin-1 has a 70% sensitivity and 95% specificity to differentiate between patients with GC and healthy individuals, while the most used cancer antigens as part of the diagnosis of GC (carcinoembryonic antigen, carbohydrate antigen 19-9 CA 19-9, carbohydrate antigen CA72-4) have low sensitivity and specificity (approximately 20–30%). This evidence concerns the gene NUCB2 and gastric cancer.